BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genaissance Pharmaceuticals, Inc. (GNSC) And Lark Technologies Inc. (LDNA) Receive Shareholder Approval For And Close Merger


10/19/2005 5:10:40 PM

NEW HAVEN, Conn., April 1 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. and Lark Technologies, Inc. (OTC Bulletin Board: LRKT) today announced that they closed the merger of Lark Technologies with and into a wholly owned subsidiary of Genaissance following approval of the merger by the stockholders of each of the two companies. The terms of the Agreement and Plan of Merger include the exchange of each outstanding share of Lark Technologies common stock for 1.81 shares of Genaissance common stock.

"I would like to welcome Lark shareholders and employees to Genaissance," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "The acquisition represents another step in the execution of our strategy to build a profitable base services business while developing proprietary products based on our HAP(TM) Technology. We now have access to a broader client base, additional GLP services, a strong and growing European operation and an experienced team focused on profitable revenue generation. In his new position, Dr. Carl Balezentis will head the effort to grow this profitable base services business, generating additional funds that will be available for the development of proprietary diagnostic and pharmaceutical products."

"Our entire team is excited to be a part of Genaissance," said Carl Balezentis, Ph.D., Senior Vice President of Genaissance and President of Lark. "We look forward to telling our combined customer base that we can provide one stop shopping for all of their DNA analysis needs."

About Genaissance Pharmaceuticals

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company's website at http://www.genaissance.com/.

About Lark Technologies

Lark Technologies, Inc., based in Houston, Texas, offers genomic services for use in pharmaceutical, diagnostic and agricultural product research and development. These services include genomic data management, microarray support, quantitative PCR, genotyping, genetically-modified organism testing, and a battery of other molecular biology services which support researchers in the pharmaceutical, biotechnology and academic sectors in their attempt to understand the mechanisms of disease and to discover and develop new drugs. Visit the company's website at http://www.lark.com/.

This press release contains forward-looking statements. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2004, and in other filings we make with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

Genaissance Pharmaceuticals, Inc.; Lark Technologies, Inc.

CONTACT: Kevin L. Rakin, President & Chief Executive Officer,Genaissance Pharmaceuticals, Inc., +1-203-786-3404, k.rakin@genaissance.com;Rhonda Chiger, Investor Relations, Rx Communications Group, +1-917-322-2569,rchiger@RxIR.com, for Genaissance



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES